94 results
8-K
EX-99.1
MAIA
MAIA Biotechnology Inc
6 Jun 24
MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
2:57pm
.
MAIA’s Phase 2 THIO-101 clinical trial is expected to near completion in 2024. The Company is also engaged in research and development for a portfolio … of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates
8-K
MAIA
MAIA Biotechnology Inc
4 Jun 24
Regulation FD Disclosure
4:06pm
, but not limited to: (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development
8-K
EX-99.3
MAIA
MAIA Biotechnology Inc
4 Jun 24
Regulation FD Disclosure
4:06pm
statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research … and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood
8-K
EX-99.1
MAIA
MAIA Biotechnology Inc
23 Apr 24
MAIA Biotechnology Announces $1.00 Million Private Placement
4:05pm
research and development activities, such as to fund the first third of the pivotal accelerated approval Part C of the THIO-101 trial in non-small cell lung … regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii
8-K
lmeabgkjpgv1 dognpi
23 Apr 24
MAIA Biotechnology Announces $1.00 Million Private Placement
4:05pm
8-K
cnw t4r732
26 Mar 24
MAIA Biotechnology Announces $1.33 Million Private Placement
3:36pm
8-K
EX-99.1
dw80x
26 Mar 24
MAIA Biotechnology Announces $1.33 Million Private Placement
3:36pm
8-K
0uqk r6s7
13 Mar 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-99.3
opmo9yrq0o qgo5
8 Mar 24
MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients
4:15pm
8-K
EX-99.1
8c25zv9j8bft9 n71
8 Mar 24
MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients
4:15pm
8-K
EX-99.2
ie5qtyjon u0zaoyozm
8 Mar 24
MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients
4:15pm
8-K
vf4f2om 6bnpxyepk
8 Mar 24
MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients
4:15pm
8-K
EX-99.1
pe2nmkh mdv1yno
6 Mar 24
Other Events
8:00am
8-K
e5maizuqjntlbgax9d
6 Mar 24
Other Events
8:00am
8-K
EX-99.2
o41nj6jd lu3
6 Mar 24
Other Events
8:00am
8-K
EX-99.1
u2mc8ing dgjw3v
27 Feb 24
MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor
5:23pm
8-K
yz4c eqb3o
27 Feb 24
MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor
5:23pm